Valneva Regains Full Rights to Chikungunya Vaccine as Serum Institute License Ends

Valneva ( (VALN) ) just unveiled an announcement.

On December 31, 2025, Valneva SE and Serum Institute of India announced they had mutually agreed to discontinue their license agreement covering Valneva’s single-shot chikungunya vaccine. By regaining full rights to the product, Valneva aims to take direct control of supply and commercialization in endemic high-risk countries, a shift intended to accelerate access in regions most affected by chikungunya and to align with its July 2024 funding agreement with CEPI, co-funded by the European Union, to support vaccine access in low- and middle-income countries. The move underscores Valneva’s strategy to tighten control over key assets in its portfolio and could strengthen its positioning in the growing market for vaccines against climate-sensitive vector-borne diseases, as chikungunya is spreading across more than 110 countries and is recognized by the WHO as a major public health problem.

The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.

Spark’s Take on VALN Stock

According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.

Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.

To see Spark’s full report on VALN stock, click here.

More about Valneva

Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs, using multiple vaccine modalities to deliver first-, best- or only-in-class products. The French group currently markets three proprietary travel vaccines, generates commercial revenues to support its R&D pipeline, and is advancing several late-stage candidates, including the only Lyme disease vaccine in advanced clinical development in partnership with Pfizer and a leading Shigella vaccine candidate, as well as vaccines targeting other global public health threats.

Average Trading Volume: 32,660

Technical Sentiment Signal: Hold

Current Market Cap: $757.4M

For a thorough assessment of VALN stock, go to TipRanks’ Stock Analysis page.